Illustrative case study · Healthcare & Life Sciences
Consumers liked one identity, and physicians chose the other.
A pharma company had two candidate corporate identities and one budget to take the winner to all four of its markets, if a single identity could carry it everywhere. We interviewed 1,200 physicians and adult consumers in four countries, and the report followed in 14 days.
Illustrative example. The company, scenario, and all figures are fictional. They show UserCue’s method and deliverable format. They do not come from any client study.
The engagement
Illustrative scenariodays, with the report, the data file and a live readout.
Practicing physicians and adult consumers in Countries A to D.
400 physicians and 800 adult consumers.
Each person rated one identity alone, then picked between the two.
A pharma company
Which corporate identity to take to all four markets
Identity test, before a global rollout
AI-moderated interviews with a monadic A/B identity test
Appeal, fit for a medicines company, final preference
Physicians and adult consumers in four countries
Headline figures
of physicians rate Identity A a fit for a medicines company, against 47% for B
of consumers find Identity B appealing, against 47% for A
of all 1,200 pick Identity B when they see both, a lead built on consumers
The question
Can one identity carry the company in four markets?
The company had outgrown an identity designed long ago and had two candidates to replace it. The rollout budget waited on one test, run the same way with physicians and with adults who fill prescriptions in each of its four markets.
Which identity appeals more, by country and audience?
Which one looks like a company that makes medicines?
Which do physicians and consumers pick when they see both?
What we did
How the study ran, start to finish.
- 1Kickoff
Two identities, one rollout budget.
Which of two identities can carry the company in all four markets? The kickoff turned it into three questions: which identity appeals more, which looks like a company that makes medicines, and which one people pick when they see both.
- 2Design
Four countries, a monadic A/B test.
Practicing physicians and adults who filled a prescription in the past year qualified: 400 physicians and 800 consumers across Countries A to D. Each saw one identity alone for appeal and fit, then both together for preference.
- 3Fielding
Every country in its own language.
Voice or text interviews in local languages mixed quant and qual at a 26-minute median; each low fit score was probed for what the company seemed to make. The researcher read all 1,364 and removed 164 for rushed responses, duplicates or retired physicians, leaving 1,200.
- 4Analysis
The audiences split in every country.
The researcher lined up physicians against consumers in each of the four countries. A pooled vote favored Identity B 57% to 43%, yet physicians chose A 73% to 27%, and no country reversed that.
- 5Readout
A 27-point fit gap among physicians.
Country by country, the researcher went through the 35-page report live with the brand team: appeal, fit and preference by audience, translated verbatims and respondent-level data. The company took Identity A to all four markets and moved B’s palette into patient materials.
What we found
Four findings from the report.
Consumers prefer Identity B and physicians prefer Identity A, in all four countries. Physicians also rate A far more fitting for a medicines company, a 27-point gap. A pooled vote picks B, 57% to 43%, only because the sample holds two consumers per physician.
Consumers find B more appealing; physicians rate the two about even.
Seeing one identity alone, 68% of consumers found Identity B appealing against 47% for Identity A. Physicians rated them close, 57% for A and 55% for B. B’s appeal with consumers ran from 66% to 70% across the four countries.
Appealing, top-two box · half of each audience per identityPhysicians see a drug company in A and a consumer brand in B.
74% of physicians rated Identity A a fit for a company that makes medicines, against 47% for B, a 27-point gap. Physicians who scored B low most often said it looked like a wellness app. Consumers rated fit closer, 66% for A and 63% for B.
In every country, consumers pick B and physicians pick A.
After seeing both identities, consumers chose B 72% to 28% and physicians chose A 73% to 27%. Physician preference for A ran from 70% to 78% across the four countries, and consumer preference for B from 67% to 77%.
Final preference after seeing both · n = 400 physicians, n = 800 consumersA pooled vote would have picked B.
Across all 1,200 respondents, Identity B wins 57% to 43%, a lead built on consumers, who make up two-thirds of the sample. Among the 400 physicians, Identity A wins by more than two to one, 73% to 27%.
“B looks like an app I would download. A looks like a company I would trust with what my patients take.”Primary care physician · Illustrative quote
Illustrative quotes
Three themes behind the numbers.
“The second one could be selling yoga mats. When I prescribe something, I want the company behind it to look like it runs a lab.”
“The blue and orange one feels friendly, like an actual person would pick up the phone if I called.”
“I chose the first one, but I’d take the second one’s colors. They’re all I remember of it.”
What the pharma company did
Three moves made with the report.
Took Identity A to all four markets.
Physicians rated A a far better fit for a medicines company, 74% against 47%, with at least 72% in every country.
Moved B’s palette into patient materials.
Patient education materials and the consumer site now use B’s colors under Identity A’s mark; 75% of consumers and 58% of physicians liked that palette.
Cut the separate versions for each market.
No country reversed the result, so the separate versions budgeted for each market came out of the rollout plan.
Illustrative example. The company, scenario, and all figures are fictional. They show UserCue’s method and deliverable format. They do not come from any client study.
Bring us your next brand question.
A senior researcher designs and presents every study.
Talk to our teamMore healthcare & life sciences studies